Rheumatoid arthritis: musculoskeletal fact sheet by Australian Institute of Health and Welfare
Musculoskeletal factsheets
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What is rheumatoid arthritis?
Rheumatoid arthritis is a chronic disease marked by 
inflammation of the joints, most often affecting the hand 
joints and both sides of the body at the same time. It can 
also affect the whole body, including the organs leading to 
problems with the heart, respiratory system, nerves and eyes.
In a healthy joint, the tissue lining the joint (called the 
synovial membrane) is very thin and produces fluid that 
lubricates and nourishes the joint. In rheumatoid arthritis, 
the immune system attacks the synovial membrane, causing 
inflammation, pain, swelling and stiffness (Figure 1). 
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Fast Facts
2% of Australians reported having  
rheumatoid arthritis—that’s 445,000 people
5 out of 8 people with  
rheumatoid arthritis are female,  
based on self-reported data
10% of people with rheumatoid  
arthritis report poor health, compared  
to 3% without rheumatoid arthritis
Who gets rheumatoid arthritis?
Based on self-reported data from the most recent Australian 
Bureau of Statistics National Health Survey (2011–12), about 
445,000 Australians (2%) reported having rheumatoid 
arthritis. It is more common for women (2.4%) than men 
(1.5%) and affects older age groups. In 2011–12, it was  
most common for those aged 65 or over (Figure 2).
How do you manage rheumatoid arthritis?
Medications 
Paracetamol, codeine, and non-steroidal anti-inflammatory 
drugs, are sometimes called the ‘first-line’ medicines in  
managing rheumatoid arthritis. These are the initial 
medicines provided for symptom relief. Stronger medications 
such as corticosteroids, disease-modifying anti-rheumatic  
drugs (DMARDs) and biologic disease-modifying  
anti-rheumatic drugs (bDMARDs) may be prescribed  
when insufficient symptom control is obtained.
In 2013–14, more than 155,000 units of bDMARDs were 
dispensed, with $281 million in benefits paid; an increase 
from $13 million when introduced in 2003–04.
Hospitals 
According to the National Hospital Morbidity Database, in 
2012–13 there were 10,411 hospitalisations with a principal 
diagnosis of rheumatoid arthritis. A total of 9,926 procedures 
were performed on people with the principal diagnosis of 
rheumatoid arthritis. Most of these procedures (74.7%) were 
for drug treatments, such as receiving corticosteroids and 
bDMARDs to reduce inflammation and pain in a joint.
Figure 2:  Prevalence of rheumatoid arthritis, 2011–12
Figure 1:  Comparison of healthy joint and joint with 
rheumatoid arthritis
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How does rheumatoid arthritis affect  
quality of life?
Soon after the onset of rheumatoid arthritis, functional 
limitations start and worsen with time. Joint damage in the 
wrist is reported as the cause of most severe limitations 
even in the early stages of rheumatoid arthritis. Work disability 
is a common problem, with 80% of sufferers likely to continue 
working at 2 years after disease onset, and 68% at 5 years. 
People with this condition are more likely to suffer from 
anxiety, depression and low self-esteem than those without 
the condition. Rheumatoid arthritis is also associated 
with increased mortality due to related complications and 
comorbidities including infections and cardiovascular disease. 
Compared to those without the condition, people with 
rheumatoid arthritis are: 
•	 3.2 times as likely to report poor health 
•	 2.7 times as likely to report very high levels of 
psychological distress 
•	 3.3 times as likely to report severe and very severe pain.
How much is spent on rheumatoid arthritis?
Based on AIHW disease expenditure data, $355 million of 
total direct expenditure allocated to arthritis and other 
musculoskeletal diseases was attributed to rheumatoid 
arthritis in 2008-09 (the most recent year for which data are 
available). This expenditure consisted of:
•	 $274 million on prescription pharmaceuticals (77.2%)
•	 $44 million on admitted patient costs (12.4%)
•	 $37 million on out-of-hospital-costs (10.4%)
Expenditure on rheumatoid arthritis is not fully captured 
in these estimates due to a lack of comprehensive data. In 
particular, expenditure on bDMARDS is not fully captured in 
these estimates.
What can I do to help prevent rheumatoid 
arthritis?
Rheumatoid arthritis is a complex disease that develops as a 
result of both genetic and environmental factors. The most 
important preventable risk factor for rheumatoid arthritis is 
not smoking. Consult your health professional for specific 
advice on:
•	 avoiding smoking
•	 achieving a healthy weight (too much weight places a 
strain on your joints)
•	 recommended foods and amounts to include as part of  
a healthy diet
•	 appropriate amounts and types of physical activity.
Where can I find out more?
AIHW online web pages: 
<http://www.aihw.gov.au/rheumatoid-arthritis/>
AIHW National Centre for Monitoring Arthritis and 
Musculoskeletal Conditions:
Tel: 02 6244 1000 
Email: ncmamsc@aihw.gov.au
Arthritis Australia: 
<http://www.arthritisaustralia.com.au/>
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